Prediagnostic antibodies to serum p53 and subsequent colorectal cancer

Lauren R. Teras, Susan M. Gapstur, Maret L. Maliniak, Eric J. Jacobs, Ted Gansler, Angelika Michel, Michael Pawlita, Tim Waterboer, Peter T. Campbell

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Background: The presence of circulating antibodies to the p53 tumor suppressor protein is a potential early detection colorectal cancer biomarker. However, studies of prediagnostic measures of p53 seropositivity in relation to colorectal cancer risk are limited. Methods: We conducted a nested case–control study of serum p53 autoantibodies and risk of colorectal cancer within the Cancer Prevention Study- II Nutrition Cohort. Among cohort participants who were cancer free at the time of blood collection, 392 were subsequently diagnosed with colorectal cancer over 11 years of follow-up. Two controls were matched to each case on birth date, blood draw date, race, and sex. Autoantibodies to p53 were detected in 41 of the 392 cases (10.5%) and 49 of the 774 controls (6.3%). Results: Participants who were seropositive for p53 antibodies before diagnosis were more likely to be subsequently diagnosed with colorectal cancer [RR ¼ 1.77; 95% confidence interval (CI), 1.12–2.78]. This association was strongest within 3 years of diagnosis (RR ¼ 2.26; 95% CI, 1.06–4.83). An association was also suggested when colorectal cancer was diagnosed 4 to <6 years after p53 measurement (RR ¼ 1.84; 95% CI, 0.89–3.79), but not 6 or more years later (RR ¼ 1.15; 95% CI, 0.44–2.99). Conclusions: If these results are confirmed, serum p53 antibodies May be useful on a panel of early detection markers for colorectal cancer. Impact: Individuals who were seropositive for p53 antibodies were twice as likely to develop colorectal cancer within the next 3 years compared with those who were seronegative. This marker is a good candidate for inclusion on an early detection marker panel for colorectal cancer. Cancer Epidemiol Biomarkers Prev; 27(2); 219–23. 2017 AACR.

Original languageEnglish (US)
Pages (from-to)219-223
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Issue number2
StatePublished - Feb 1 2018
Externally publishedYes

ASJC Scopus subject areas

  • Epidemiology
  • Oncology


Dive into the research topics of 'Prediagnostic antibodies to serum p53 and subsequent colorectal cancer'. Together they form a unique fingerprint.

Cite this